PMID- 33080103
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20221005
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 24
IP  - 22
DP  - 2020 Nov
TI  - Histamine receptor 1 is expressed in leukaemic cells and affects differentiation 
      sensitivity.
PG  - 13536-13541
LID - 10.1111/jcmm.15930 [doi]
AB  - Despite the success of immunotherapy in several haematological neoplasms, the 
      effectiveness in acute myeloid leukaemia (AML) is still controversial, partially 
      due to the lack of knowledge regarding immune-related processes in this disease 
      and similar neoplasias. In this study, we analysed the role and expression of 
      histamine receptor 1 (HRH1) in haematological malignancies. Although the 
      histamine receptor type 1 was widely expressed in healthy and malignant 
      haematopoiesis, especially along the myeloid lineage, HRH1 lacked a relevant role 
      in survival/proliferation and chemoresistance of AML cells, as analysed by HRH1 
      knockdown (KD) and pharmacological modulation. However, HRH1-mediated signalling 
      was critical for the activation of the differentiation process induced by several 
      agents including all-trans retinoic acid, establishing a role for HRH1 in myeloid 
      differentiation. Pharmacological activation of Erk was able to partially restore 
      differentiation capacity in HRH1 KD AML cells, suggesting that HRH1 signalling 
      acts upstream MAPK-Erk pathway. As an indirect consequence of our results, 
      treatment-related histamine release is not expected to confer a proliferative 
      advantage in leukaemic cells.
CI  - (c) 2020 The Authors. Journal of Cellular and Molecular Medicine published by 
      Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
FAU - Cornet-Masana, Josep M
AU  - Cornet-Masana JM
AD  - Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.
AD  - Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP), 
      Badalona, Spain.
AD  - Faculty of Medicine, University of Barcelona, Barcelona, Spain.
FAU - Banus-Mulet, Antonia
AU  - Banus-Mulet A
AD  - Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.
AD  - Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
FAU - Cuesta-Casanovas, Laia
AU  - Cuesta-Casanovas L
AD  - Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.
AD  - Faculty of Biosciences, Autonomous University of Barcelona, Barcelona, Spain.
FAU - Carbo, Jose M
AU  - Carbo JM
AD  - Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.
FAU - Guijarro, Francesca
AU  - Guijarro F
AD  - Faculty of Medicine, University of Barcelona, Barcelona, Spain.
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, 
      Spain.
AD  - Department of Hematology, Hospital Clinic, Barcelona, Spain.
FAU - Torrente, Miguel Angel
AU  - Torrente MA
AD  - Faculty of Medicine, University of Barcelona, Barcelona, Spain.
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, 
      Spain.
FAU - Esteve, Jordi
AU  - Esteve J
AD  - Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.
AD  - Faculty of Medicine, University of Barcelona, Barcelona, Spain.
AD  - Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, 
      Spain.
AD  - Department of Hematology, Hospital Clinic, Barcelona, Spain.
FAU - Risueno, Ruth M
AU  - Risueno RM
AUID- ORCID: 0000-0003-4048-9536
AD  - Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201020
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Histamine H1)
SB  - IM
MH  - Biomarkers
MH  - Cell Differentiation/*genetics
MH  - Cell Line, Tumor
MH  - *Gene Expression Regulation, Leukemic
MH  - Hematopoiesis/genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunophenotyping
MH  - Leukemia, Myeloid, Acute/genetics/metabolism/pathology
MH  - Receptors, Histamine H1/*genetics/metabolism
PMC - PMC7701509
OTO - NOTNLM
OT  - HRH1
OT  - differentiation
OT  - histamine
OT  - leukaemia
COIS- RMR is a shareholder of Leukos Biotech.
EDAT- 2020/10/21 06:00
MHDA- 2021/05/13 06:00
PMCR- 2020/11/01
CRDT- 2020/10/20 17:11
PHST- 2020/04/22 00:00 [received]
PHST- 2020/08/14 00:00 [revised]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
PHST- 2020/10/20 17:11 [entrez]
PHST- 2020/11/01 00:00 [pmc-release]
AID - JCMM15930 [pii]
AID - 10.1111/jcmm.15930 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2020 Nov;24(22):13536-13541. doi: 10.1111/jcmm.15930. Epub 2020 
      Oct 20.